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Background. Electrochemotherapy is becoming a well-established treatment for malignancies of skin and non-skin 
origin and its use is widening across Europe. The technique was developed and optimized from solid experimental 
and clinical evidence. A consensus document is now warranted to formalize reporting results, which should strengthen 
evidence-based practice recommendations. This consensus should be derived from high quality clinical data col-
lection, clinical expertise and summarizing patient feedback. The first step, which is addressed in this paper, aims to 
critically analyze the quality of published studies and to provide the recommendations for reporting clinical trials on 
electrochemotherapy.
Methods. The quality of reporting in published studies on electrochemotherapy was analyzed in order to produce 
procedure specific reporting recommendations. A comprehensive literature search of studies published from 2006 to 
2015 was performed followed by qualitative analysis of manuscripts assessing for 47 quality criteria grouped into four 
major clusters: (1) trial design, (2) description of patient population, (3) description of treatment delivery and patient 
outcome, (4) analysis of results and their interpretation. The summary measure during literature assessment was the 
proportion of studies fulfilling each manuscript quality criteria.
Results. A total of 56 studies were screened, from the period 2006 to 2015, of which 33 were included in the quali-
tative analysis, with a total of 1215 patients. Overall, the quality of reporting was highly variable. Twenty-four reports 
(73%) were single-center, non-comparative studies, and only 15 (45%) were prospective in nature (only 2 of them were 
entered into a clinical trials registry). Electrochemotherapy technique was consistently reported, with most studies 
(31/33) adhering closely to published standard operating procedures. The quality of reporting the patient population 
was variable among the analyzed studies, with only between 45% and 100% achieving dedicated quality criteria. 
Reporting of treatment delivery and patient outcome was also highly variable with studies only fulfilling between 3% 
and 100%. Finally, reporting study results critically varied, fulfilling from 27% to 100% of the quality criteria. Based on the 
critical issues emerging from this analysis, recommendations and minimal requirements for reporting clinical data on 
electrochemotherapy were prepared and summarized into a checklist.
Conclusions. There is an increasing body of published clinical data on electrochemotherapy, but more high quality 
clinical data are needed. Published papers often lack accurate description of study population, treatment delivery 
as well as patient outcome. Our recommendations, provided in the form of a summary checklist, are intended to 
ameliorate data reporting in future studies on electrochemotherapy and help researchers to provide a solid evidence 
basis for clinical practice.  
Key words: electrochemotherapy; clinical trials, recommendations
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Introduction
Electrochemotherapy is becoming a well-estab-
lished non-thermal ablative technique for malig-
nancies of skin and non-skin origin.1,2 The medical 
applications of electrochemotherapy are based on 
the principle of electroporation, which dates back 
to 1982, when sequences of electric pulses were 
applied to deliver naked DNA molecules within 
mouse lyoma cells.3 Preclinical studies carried out 
by several research groups, coupled with technical 
developments, culminated in the clinical applica-
tion of electroporation during the early 1990s.4-13 
These initial data on electroporative uptake of mol-
ecules are viewed as seminal for various biotechno-
logical and medical applications.14,15 The principle 
of electrochemotherapy is the use of electropora-
tion to enhance chemotherapeutic drug delivery. 
Two agents, bleomycin or cisplatin, can achieve 
a several fold increase in their intracellular avail-
ability, and consequently cytotoxicity, when the 
tumor tissue is exposed to reversible electropora-
tion and transient cell membrane permeabiliza-
tion, thus achieving an optimal intratumor drug 
distribution.7,16-18 Electrochemotherapy has proven 
effective for the treatment of different tumor his-
totypes, including both skin and non-skin cancers, 
as well as for the palliation of metastases involving 
cutaneous and subcutaneous tissues.19-22 The treat-
ment of primary skin tumors is largely restricted 
to multifocal cutaneous tumors, most notably some 
selected cases of basal cell carcinoma, when tumor 
anatomical location and patient medical conditions 
contraindicate more aggressive treatments.23 
The publication of the European Standard 
Operating Procedures of Electrochemotherapy 
(ESOPE) in 2006 facilitated a broad acceptance 
of electrochemotherapy for treatment of cutane-
ous tumors and metastases.24 Over a number of 
years, several clinical reports have confirmed its 
effectiveness. Interestingly, the vast majority of 
studies used the Standard Operating Procedure 
(SOP) as a guideline for electrochemotherapy. 
The availability of SOP allowed for reproduc-
ibility and improvement of results in the clinical 
practice. Several large follow up series confirmed 
the efficiency of electrochemotherapy. A recent 
meta-analysis of the use of electrochemotherapy 
in the treatment of cutaneous metastasis places 
it well amongst other, more established, treat-
ment options.2 Recently, electrochemotherapy has 
also been recognized by the National Institute for 
Health and Care Excellence (NICE) as an integral 
part of the multidisciplinary treatment for pa-
tients with skin metastases of non-skin origin and 
melanoma (NICE interventional procedure guid-
ance IPG 446, http://www.nice.org.uk/guidance/
ipg446). More recently, electrochemotherapy has 
been introduced into the treatment of deep-seated 
and endoluminal tumors.25-28 The first clinical re-
port on visceral metastases indicates its effective-
ness, and suggests a possible role of electrochemo-
therapy for the treatment of liver metastases, es-
pecially when located close to major blood vessels 
and when not manageable with surgery or other 
ablative techniques.29 
Overall, literature data from Web of Science da-
tabase indicate a steady increase in number of pub-
lications and their citations under the key word 
“electrochemotherapy” (Figure 1A,B) and “clini-
cal electrochemotherapy” (Figure 1C,D). Despite a 
steady increase in the number of published reports, 
a higher quality and standardization of reported 
studies is needed to improve and support a truly 
evidence based practice. In our study we only in-
cluded papers published after 2006, specifically on-
ly to include reports published after the Standard 
Operating Procedures (SOP).24 
The purpose of this recommendation paper is 
to provide practical recommendations in order to 
improve the precision of reported clinical stud-
ies on electrochemotherapy (a summary checklist 
is provided as Supplementary file). This, in turn, 
we hope will stimulate the scientific community 
to report research using these guidelines to give 
comprehensive reports on areas including study 
design, definition of study endpoints, patient se-
lection criteria, treatment plan and outcome assess-
ment. The adoption of more precision in reporting 
will enable researchers and clinicians to perform 
more meaningful outcome comparisons with other 
ablative techniques, to clarify the direction for fu-
ture research, and to produce more evidence-based 
practice. It is our hope that these advancements 
may improve patient selection, resource allocation, 
and ultimately patient outcome. 
This report was prepared based on initiative 
of the Steering Committee of the COST TD 1104 
Action (www.electroporation.net) and in response 
to a general call for increased awareness and con-
cern for low quality reporting practice30; moreover, 
it has been prepared by the committee within the 
Working group of Medical applications of elec-
troporation, in COST action TD 1104 EP4Bio2Med, 
and is included in the series of publications ad-
dressing the same topic in preclinical research in 
electroporation as well as in the pulsed electric 
fields for industrial purposes.31
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Several guidelines exist with the aim of assur-
ing sound research practices, and improving the 
quality of clinical trials and, ultimately, allow for 
generalizable results. At a basic level, Good Clinical 
Practice (GCP) represents an international ethical 
and scientific quality standard for designing, con-
ducting, recording and reporting trials that involve 
the participation of human subjects. At a higher 
level, dedicated guidelines and recommendations 
have been developed according to the specific type 
of study performed. For instance, the STROBE 
statement (www.strobe-statement.org) indicates a 
checklist for details that should be reported in ob-
servational trials; the Consolidated Standards of 
Reporting Trials (CONSORT) statement (www.con-
sort-statement.org/consort-statement/) provides 
guidance for reporting the aim, methods, results 
and implications of randomized controlled trials; 
the PRISMA statement (www.prisma-statement.
org) indicates preferred reporting for systematic 
reviews; finally, the REporting recommendations 
for tumor MARKer prognostic studies (REMARK, 
www.equator-network.org/reporting-guidelines/
reporting-recommendations-for-tumour-marker-
prognostic-studies-remark/) suggest guidelines to 
provide relevant information about study design, 
preplanned hypotheses, patient and specimen char-
acteristics, assay methods, and statistical analyses 
when evaluating tumor markers in oncology. In ad-
dition, these guidelines provide helpful suggestions 
on how to present data and important elements to 
include in discussions. Although these guidelines 
provide a fundamental guidance for conducting a 
valid clinical trial and reporting generalizable find-
ings, nonetheless it is recognized that there is a 
need for specialty-specific guidelines and that these 
guidelines will lead to improvement in the quality 
of reports and to higher impact publications.32,33 In 
the field of electrochemotherapy, comprehensive 
meta-analyses or Cochrane style reviews of effi-
ciency are hampered by the lack of some relevant 
clinical data in published reports. Therefore, we 
evaluated the published papers on clinical elec-
trochemotherapy and identified possible pitfalls 
in data reporting. On this basis, we prepared rec-
ommendations for improving the quality of future 
studies and fostering further rational development 
of electrochemotherapy. 
Systematic review and qualitative 
analysis of publications
Methods
The initial step was to identify and access all pub-
lished trials evaluating the efficacy of electrochem-
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FIguRe 1. Search in Web of Science demonstrates a steady increase in number of publications under the key word 
“electrochemotherapy” (a,B) as well under the “electrochemotherapy, clinical” (C,D). The Meta data indicate the expanding field. 
A B
C D
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otherapy in the treatment of tumors including skin 
cancers, cutaneous/subcutaneous metastases from 
other histotypes, deep-seated tumors or visceral 
metastases. 
From October 4 to 10, 2015, we conducted a 
comprehensive literature assessment that included 
searches of Medline (EBSCO), Pubmed (NLM), 
Web of Science and Embase. The search terms used 
were “electrochemotherapy”, “electrochemother-
apy” AND “clinical trial”. We limited our search 
to humans. Articles published from January 2006 
to September 30, 2015 were retrieved. We included 
studies on the clinical application of electrochemo-
therapy regardless of study design (both prospec-
tive and retrospective) patient population, tumors 
histotype and anatomical location or electrochem-
otherapy treatment protocol. However, treatment 
outcome had to include tumor response and fol-
low-up tumor control evaluation, procedural mor-
bidity and toxicity or patient quality of life. Two 
of the authors (LGC and SV) and an external col-
laborator with experience in clinical trials indepen-
dently screened the retrieved studies based on the 
title, key words, and abstract to exclude non-rele-
vant and non-English written studies. After com-
pletion of all searches, duplicates were removed 
and only the most recent report from follow-up 
series was included in order to avoid overlapping 
series. Both retrospective and prospective studies 
were included, while case reports and small se-
ries were excluded because of their intrinsic lower 
level of evidence (the minimum number of pa-
tients was arbitrarily set at 9). Published reviews 
on electrochemotherapy were similarly excluded, 
but their reference list was reviewed in order to 
identify possible additional studies. Studies whose 
main purpose was unrelated to electrochemo-
therapy efficacy and biological studies (i.e., those 
exploring immune effects of treatment) were also 
excluded, unless clear and standardized descrip-
tion of patient outcome was retrievable from the 
manuscript. Studies that did not meet the inclusion 
criteria were discarded during the initial review. 
When uncertainty existed in the abstract evalu-
TaBle 1. Manuscript quality criteria 
Manuscript quality criteria
Trial design Description of Patient population
Treatment delivery and outcome 
assessment Analysis of results and interpretation
  1. Prospective trial 1. Setting   (curative / palliative) 1. Type of anaesthesia 1. Summary of trial endpoints
  2. Trial registration 2. Drug route    and dosages
  3. Comparative trial 2. Demographic data (in tabular form) 3. Pulse generator 2. Predictive factors
  4. Mention of trial design 4. EP parameters
  5. Multicenter study 3. No of tumors 5. Electrode description 3.  Other patient outcome parameters
  6. Mention of sponsor 6. Tumor safety margins indicated
  7. Trail hypothesis and sample size 4. Tumor location 7. Deviation from SOPs 4. Results interpretation
  8. Informed consent 5. Tumor histotype 9. Criteria for retreatment 5. Comparison to historical controls
  9. EC approval 8. Tumor coverage with EP
10. Structured abstract 10. Total No of ECT sessions
11. Rationale of the trial 6. Tumor size 11. ECT sessions requireda 6. Future directions
12. A priori inclusion criteria 12. Toxicity criteria
13. Follow-up dates 7. Visceral mts indicated 13. Response criteria 7. COI statement
14. Statistical methods 14. Evaluation of tumor control
15. Software used 8. Concomitant treatments 15. ECT successb
16. C.I., p-values 16.  Keep track of patients lost to follow-up
C.I. = confidence intervals; COI = conflict of interest statement; EC = Ethic Committee; EP = electric pulses (including number, duration and amplitude); mts = metastases; SOPs 
= Standard Operating Procedures.
a Number of electrochemotherapy (ECT) sessions required for achieving response (either complete or partial) on baseline tumors
b Decision rule for determining ECT success
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ation, we retrieved and assessed the full text. A 
third author (GS) resolved differing opinions. Full 
text of the included articles was independently re-
viewed by two of the authors using a predefined 
checklist quality criteria. These quality criteria 
were discussed and agreed among the authors in 
a series of operative meetings which were hold 
during the 1st World Congress on Electroporation 
in Portoroz, Slovenia, between September 6 to 10 
2015 and were also based on deliberations at the 
Recommendation paper workshop organized by 
COST TD1104 on 28th March 2014 in Copenhagen, 
Denmark. The checklist was also adapted from 
similar reporting standard guidelines in the field 
of neuro-oncology, isolated limb perfusion and in 
phase II cancer trials.34-36 As a result, we had a fi-
nal count of 47 quality criteria that were clustered 
into four domains: trial design, description of pa-
tient population, treatment delivery and outcome 
assessment, and analysis of results and their inter-
pretation (Table 1). The summary measure during 
literature assessment was the proportion of studies 
fulfilling each manuscript quality criteria.
Results
A total of 56 papers were initially identified. Of 
these, only 33 reports were finally retained in the 
qualitative synthesis; the reasons for exclusion of 
the remaining reports are listed in Figure 2. 
A summary of the studies included in the final 
analysis is presented in Table 2.20-22,29,37-65 The total 
number of patients across all studies was 1215. 
Electrochemotherapy protocol was following the 
SOP as defined in ESOPE study in all but two cas-
es.40,65
The majority (24/33) of reports were single-cent-
er studies. There were 24 tumor-specific studies 
(melanoma, n=8; breast cancer, n=5; head and neck 
squamous cell carcinoma, n=4; Kaposi sarcoma, 
n=3; pancreatic cancer, n=1; colorectal cancer, n=1; 
soft tissue sarcomas, n=1; vaginal squamous cell 
cancer, n=1) and 9 studies including heterogene-
ous histologies. Response assessment was based 
on clinical evaluation in all except 3 studies on 
pancreatic cancer41, liver metastases from colorec-
tal cancer29, and chest wall recurrence from breast 
cancer57, where response assessment was radio-
logical (ultrasound scan, magnetic resonance im-
aging, computed tomography, or fluorine-18-de-
oxyglucose PET-CT scan). Details of the quality 
criteria used to assess trial design are presented 
in Figure 3. Less than half (15/33, 45%) of studies 
were prospective and only two of them (6%) were 
entered into a publicly accessible clinical trials reg-
istry.29,57 Eighteen percent (6/33) of papers repre-
sented the report of a multicenter study. There was 
a single comparative trial (an internally controlled 
Identification
Records identified 
through PubMed 
database search
n = 56
Records excluded  
due to duplicaten
n = 2
Records excluded 
(irrelevant, pre-clinical 
non-human, non-English
n = 4
Records excluded 
• Not a trial: n = 4
• Case report: n = 9
• Small series: n = 4
• Duplication / overlapping: n = 2
Screening
Records after  
duplicate removal
n = 54
Eligibility
Full-text article  
for eligibility
n = 50
Included
Studies included in the 
qualitative analysis
n = 33
FIguRe 2. PRISMA flow diagram of identification, screening, eligibility and inclusion 
of studies.
45Prospective trial
6Trial registration
3Comparative trial
9Mention of trial design
18Multicenter study
0Mention of sponsor
12Trial hypothesis and sample size
97Informed Consent
88Ethic Committee approval
85Structured abstract
85Rationale of the trial
70A prori definition of inclusion criteria
58Follow-up dates
64Statistical methods
64Software
54Confidence Intervals, p-values
0 20 40 60 80 100
% of included studies (n=33)
FIguRe 3. Assessment of published studies according to quality criteria concerning 
trial design. 
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TaBle 2. Trials identified included in the qualitative analysis
Study, year Setting No of pts Tumor histotype ECT protocol
Rotunno, 2015 37 Two-center, Italy 55 non-melanoma SC ESOPE
Cabula, 2015 38 Multi-center, Italy 125 BC ESOPE
Mozzillo, 2015 39 Single-center, Italy 15 melanoma ESOPE
Landstrom, 2015 40 Single-center, Sweden 19 HNSCC Other a
Granata, 2015 41 Single-center, Italy 13 pancreatic cancer ESOPE
Kreuter, 2015 42 Multi-center, Germany 56 various ESOPE
Quaglino, 2015 43 Multi-center, Europe 121 various ESOPE
Mir-Bonafé, 2015 44 Single-center, Spain 31 melanoma ESOPE
Campana, 2014 45 Single-center, Italy 39 HNSCC ESOPE
Ricotti, 2014 46 Single-center, Italy 30 melanoma ESOPE
Campana, 2014 47 Single-center, Italy 55 BC ESOPE
Edhemovic, 2014 29 Single-center, Slovenia 16 CRC-liver mts ESOPE b
Seccia, 2014 48 Single-center, Italy 9 HNSCC ESOPE
Campana, 2014 50 Two-center, Italy 34 STS ESOPE
Solari, 2014 51 Single-center, Italy 39 various ESOPE
Di Monta, 2014 52 Single-center, Italy 19 KS ESOPE
Caracò, 2013 49 Single-center, Italy 60 melanoma ESOPE
Perrone, 2013 53 Single-center, Italy 9 V-SCC ESOPE
Benevento, 2012 54 Single-center, Italy 12 BC ESOPE
Mevio, 2012 55 Single-center, Italy 15 HNSCC ESOPE
Campana, 2012 20 Single-center, Italy 35 BC ESOPE
Latini, 2012 56 Single-center, Italy 18 KS ESOPE
Matthiessen, 2012 57 Single-center, Denmark 12 BC ESOPE
Gargiulo, 2012 58 Single-center, Italy 52 non-melanoma SC ESOPE
Campana, 2012 21 Single-center, Italy 85 melanoma ESOPE
Curatolo, 2012 59 Two-center, Italy 23 KS ESOPE
Kis, 2011 60 Single-center, Hungary 9 melanoma ESOPE
Matthiessen, 2011 22 Two-center, Denmark-UK 52 various ESOPE
Skarlatos I, 2011 61 Multi-center, Greece 52 various ESOPE
Campana, 2009 62 Single-center, Italy 52 various ESOPE
Quaglino, 2008 63 Single-center, Italy 14 melanoma ESOPE
Larkin, 2007 64 Single-center, Ireland 30 various ESOPE
Gaudy, 2006 65 Single-center, France 12 melanoma Other c
BC = breast cancer; ECT = electrochemotherapy; CRC-liver mts = colorectal cancer liver metastases; HNSCC = head and neck squamous cell cancer; 
KS = Kaposi’s sarcoma; SC = skin cancer; STS = soft tissue sarcomas; V-SCC = vaginal squamous cell cancer 
a  Intratumoral BLM injection (1000 IU/cm3 and tumor electroporation by means of six 1100 V/cm square wave pulses with 0.1 ms duration 
b  In this trial, the ESOPE protocol was integrated by the application of variable geometry electrodes for the treatment of deep visceral metastases. 
c  Intratumoral BLM injection (concentration, 4 mg/mL; dose, 1 mg/cm3 of tumor volume was followed, after 10 minutes, by the application of electric 
pulses (six 100 µsec-long pulses, 4 pulses/sec, electric field >600V/cm
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study with intrapatient randomization of mela-
noma metastases to intralesional bleomycin versus 
intralesional bleomycin followed by electric puls-
es)65; a formal sample size calculation or analysis of 
“intent-to-treat” population was found in only 4/33 
(12%) studies.20,50,57,65 
Details of the quality criteria used to assess the 
description of patient population are presented in 
Figure 4. Treated tumors were described in detail in 
most reports: number of tumors, 94%; tumor loca-
tion, 100%; tumor histotype, 100%; tumor size, 91%. 
On the other hand, additional clinical information 
was less frequently reported: study setting -pallia-
tive/curative-, 54%; presence of visceral metastases, 
54%; concomitant oncologic treatments, 45%. 
Details of the manuscript quality criteria used 
to assess the description of treatment delivery and 
response assessment are presented in Figure 5. 
Treatment details were accurately described in 
most reports: type of anaesthesia, 32/33 (97%); 
drugs, 33/33 (100%); pulse generator, 33/33 (100%); 
electrode types, 31/33 (93%); electric pulse param-
eters, 32/33 (97%). The criteria for response assess-
ment were clearly stated in 29/33 (88%) of studies, 
while toxicity criteria were indicated in only 14/33 
(42%) of papers. 
Details of the quality criteria used to assess 
the analysis of results and their interpretation are 
presented in Figure 6. The majority of reports in-
cluded a critical analysis: interpretation of results, 
33/33 (100%); comparison to historical control, 
25/33 (76%); indication of possible future direc-
tions, 33/33 (100%); conflict of interest statement, 
27/33 (82%). On the contrary, only a minority of 
them fulfilled other specific quality criteria: sum-
mary of primary and secondary endpoints, 13/33 
(39%); indication of predictive factors, 9/33 (27%); 
additional patient outcome parameters, 9/33 (27%).
Based on the results of this analysis, the con-
sensus between authors was to recommend some 
minimal requirements for reporting clinical data in 
future studies.
Recommendations and minimal 
requirements for reporting 
clinical trial results on 
electrochemotherapy
Trial design
Any consolidation of the evidence base of electro-
chemotherapy requires that reports adhere strictly 
to research reporting standards and are the re-
sult of well-designed clinical trials. Much of these 
54Setting, curative/palliative
91Demographic data in tabular form
94No. of tumors
100Tumor location
100Tumor histotype
91Tumor size
54Visceral metastases indicated
45Indication of concomitant treatments
0 20 40 60 80 100
% of included studies (n=33)
FIguRe 4. Assessment of published studies according to quality criteria concerning 
description of patient population. 
97Type of anaesthesia
100Drug, route and dosages
100Pulse generator
97EP parameters
93Electrode type
24Safety margins
6Deviation from SOPs indicated
9Tumor coverage with EP
39Criteria for retreatment
79Total No of ECT sessions
36No of ECT required on baseline tumors
42Toxicity criteria
88Response criteria
36Evaluation of tumor control
6Decision rule for determining success
3Track of patients lost to follow-up
0 20 40 60 80 100
% of included studies (n=33)
FIguRe 5. Assessment of published studies according to quality criteria concerning 
treatment delivery and outcome assessment. 
ECT = electrochemotherapy; EP = electric pulses.
39Summary of trial endpoints
27Predictive factors
27Other outcome parameters (QoL, PRO)
100Results interpretation
76Comparison to historical controls
100Future direction
82COI statement
0 20 40 60 80 100
% of included studies (n=33)
FIguRe 6. Assessment of published studies according to quality criteria concerning 
analysis of results and interpretation. 
COI = conflict of interest statement; PRO = patient reported outcomes; QoL = quality of life.
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topics are covered by STROBE (STrengthening 
the Reporting of Observational studies in 
Epidemiology, http://www.strobe-statement.
org/) checklist and CONSORT (CONsolidated 
Standards of Reporting Trials, http://www.consort-
statement.org/checklists/view/32-consort/66-title) 
guidelines which should be adhered to as much 
as possible when reporting observational studies 
and randomized controlled trials, respectively. 
Incorporation of these electrochemotherapy guide-
lines will further improve the quality of the reports. 
So far, only phase I-II single-arm trials have been 
reported, with the exception of a single small-sized 
study, which included an intra-patient randomi-
zation of tumors to direct bleomycin injection or 
bleomycin injection followed by electroporation.65 
It is likely that improving the evidence base will 
involve conducting properly designed, prospec-
tive comparative - possibly randomized - clinical 
trials in order to perform accurate analyses of the 
advantages of electrochemotherapy against other 
ablative procedures or alternative local treatments. 
Of utmost importance, future trials should aim to 
be prospective and preferably multicentric, with 
clearly defined endpoints and inclusion criteria. It 
is also advisable that all trials should be registered 
at publicly accessible clinical trials registries, (e.g., 
clinicaltrials.gov, ISRCTN registry at http://www.
isrctn.com, WHO registry at www.apps.who.int/
trialsearch, or similar) and approved by institu-
tional review boards or respective national bodies. 
Finally, according to the current requirements of 
most scientific journals – which refer to the rec-
ommendation of the International Committee of 
the Medical Journal Editors (ICMJE, http://www.
icmje.org/), manuscripts should conform to well-
defined general principles and include, for exam-
ple, a statement about patient informed consent, 
modalities of study conduct, as well as authors 
conflicts of interest.
Key elements of trial design:
•  Explanation of the rationale of the study
•  Description of trial design and sponsorship
•  Indication of trial endpoints
•  Indication of inclusion and exclusion criteria
•  Trial approval and registration
•  Informed consent statement
Description of patient population
Electrochemotherapy was initially used with pal-
liative intent. First trials demonstrated remark-
able efficiency in the treatment of skin metastases 
from malignant melanoma.21,60,63 Subsequently, 
electrochemotherapy was also evaluated for the 
treatment of other tumor histotypes (e.g., non-
melanoma skin cancers and cutaneous metastases 
from other tumor histotypes) with equally high 
success.20,37-38,47,57-58 Reports of small series indicate 
also its possible usefulness in the treatment of pri-
mary basal cell carcinomas23 and a clinical trial is 
currently ongoing comparing the effectiveness of 
electrochemotherapy to standard surgical resec-
tion and is due to report 5 year follow up data 
next year (EudraCT Number: 2010-019260-37). 
A particular advantage of electrochemotherapy 
is that it is a reliable alternative treatment option 
for patients who have exhausted more conven-
tional oncological treatments or are judged unfit 
for or refuse repetitive surgical interventions.47 
Therefore, future reports need to include detailed 
description of patient’s demographic and clinical 
data including detailed description of previous 
treatments. A detailed description of tumor loca-
tion, histotype as well as number and size of the 
electrochemotherapy target and non-target lesions 
is paramount. Authors should also specify whether 
targeted lesions had previously received irradia-
tion or not, whether visceral metastases are present 
and whether the treatment is intended as pallia-
tive or curative. Additionally, since electrochemo-
therapy is finding its place among other oncologic 
treatments, and will be increasingly used also in 
combination with them, an accurate record of con-
comitant treatments is also advisable.66
Key elements of patient population:
•  Patient demographic data (in tabular form)
•  Setting - palliative or curative
•  Tumor histology 
•  Disease stage (lymph node or visceral 
metastases)
•  Description of target lesions treated with 
electrochemotherapy (anatomical location, 
number and size )
•  Previous local treatments
•  Concomitant oncological treatments
•  Adjuvant and / or following oncological 
treatments
Treatment information 
The treatment is applied by performing a proce-
dure conjugating the administration of a drug and 
local application of electric pulses. In one “session” 
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or “cycle” a single or several tumor nodules can 
be treated. Since the procedures can be repeated 
on the same and also on newly emerged tumor 
nodules, patient treatment may require one or 
more sessions of electrochemotherapy. Therefore, 
reports should clearly indicate how many sessions 
(or cycles) were needed for the treatment of base-
line tumors and, overall, for patient management. 
If retreatment is necessary, the indication should 
be clear, detailing previous response and disease 
status in target and non-target tumors. In order 
to ensure the maximum efficacy, electrochemo-
therapy needs two key elements: the presence 
of a cytotoxic agent within tumor tissue and the 
adequate coverage of tumor with electric pulses 
above the threshold of reversible membrane elec-
troporation.67 The results of the ESOPE study and 
the adoption of SOP that were prepared within 
the ESOPE project (QLK-2002-02003) were of 
great importance for the development of electro-
chemotherapy.68,24 In fact, they provided practical 
guidelines and standardization of the procedure. 
The clinical data evaluation demonstrated that the 
use of guidelines and a standardized protocol ena-
bled to reach the same level of effectiveness also 
in the centers without previous experience with 
electrochemotherapy.17 The ESOPE study provid-
ed evidence for electrochemotherapy in the treat-
ment of skin metastases of different histotypes.68 It 
included use of bleomycin or cisplatin as chemo-
therapeutics, different routes of administration 
(intravenous or intratumoral) and the use of either 
local or general anaesthesia. The pulse parameters 
(number, sequence and amplitudes) for different 
electrodes were however well defined within the 
Cliniporator project.45 A specific electric pulse gen-
erator has been consistently used with different 
electrodes, according to the size, depth and ana-
tomical location of treated tumors. 
As confidence with the procedure has devel-
oped, treatment indications have also widened. 
The first studies were based on patients with tu-
mors less than 3 cm, however lesions greater than 
3 cm are now routinely treated57,62,69, representing a 
natural development of the field based on success 
with smaller tumors for which the ESOPE guide-
lines were prepared. As such, there is a need to 
adapt and revise the SOP and this is already under-
way. Furthermore, new producers of electric pulse 
generators are coming to the market, and new elec-
trodes with different design for different treatment 
settings are emerging. All these changes will make 
the clinical data evaluation even more challenging. 
First of all, to address this topic, future reports will 
need to state the type of anesthesia used (local or 
general; drugs and doses), the chemotherapeutic 
agent, drug concentration and dose used, which 
both depend on the route of administration. The 
duration of bolus injection, as well as time interval 
between the drug administration and application 
of electric pulses, should be specified. The type of 
electric pulse generator as well as the type of elec-
trodes and their manufacturers should be reported. 
Additional information should include if the pulse 
generator is under software control and the specifi-
cation of the version of that software. If new types 
of electrodes are used, a detailed description of the 
design and the sequence and amplitude of pulses is 
needed. It must be clearly stated whether applied 
electrodes are needle or plate, the distance between 
the electrodes, their shape and size, the amplitude 
of applied electric pulses, their duration, number 
and repetition frequency. Furthermore, the total 
number of pulse deliveries, as well as the time 
interval required for electrode applications after 
drug injection, should be specified. Additionally, 
the report of adequate or inadequate coverage of 
the tumor as well as the way the pulses are applied 
(e.g., from the margins to the tumor centre or if the 
pulses were applied in 4+4 (perpendicular) config-
uration each time) would also be advisable, when 
possible (Figure 7).70 
Electrochemotherapy has a high therapeutic 
index, therefore after successful treatment mini-
mal damage is observed on normal surrounding 
tissues. During treatment, it is also possible for 
the treating physician to include a safety margin 
around the target tumor, depending on tumor 
size, biologic aggressiveness and propensity for 
tumor safety margins 
target volume 
(clinically apparent tumor) 
clinically occult  
satellite metastases 
FIguRe 7. Importance of covering whole tumor area along with safety margins. 
Reporting of the type of electrode applied is essential. 
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developing satellite lesions such as in the case of 
malignant melanoma or soft tissue sarcomas. In 
order to improve reporting, the information about 
the safety margins and their extent should also be 
reported. In addition, electrochemotherapy can be 
repeated several times (however there is a ceiling 
for the total lifetime dose of bleomycin), according 
to tumor response and disease behavior.62,63 This 
fundamental aspect is not covered by the currently 
available SOP. For providing a more informative 
report, data regarding repetitive treatments should 
be included, along with the description on what 
basis the retreatment was performed and at what 
time interval. 
Key elements on treatment information:
•  Indication of electroporation protocol 
(adherence to SOP or other)
•  Type of anesthesia
•  Drug (producer)
•  Drug details (dose, concentration and route of 
administration 
•  Time interval between drug administration 
and application of electric pulses
•  Technical details of the electric pulse 
generator, including type, manufacturer and 
version of software, if applicable 
•  Information about the electrodes used, for 
respective tumor(s) 
•  Number of electric pulses application per 
tumor
•  Inclusion of a report on electrical parameters 
(n, T, U, I, f)*
•  Adequacy of tumor treatment (treatment 
application success rate) 
•  Extent of the safety margins treated
•  Number of treatment sessions (with interval 
between sessions)
* Legend: n = number; T = duration of pulses; U = voltage 
amplitude applied; I = measured current; f = pulse repetition 
frequency
Outcome assessment
The early studies on electrochemotherapy antitu-
mor activity have carefully evaluated the response 
of treated tumors. Response assessment was initial-
ly performed by the bidimensional WHO criteria.71 
According to these criteria, baseline and post-treat-
ment tumor size is determined by bidimensional 
measurements e.g. the sum of the two longest di-
ameters in the perpendicular dimensions. The tu-
mor response to treatment is divided into four cat-
egories (complete response, partial response, sta-
ble disease, progressive disease, according to the 
change from baseline tumor measurement). 
Indeed, most past studies were focused on tu-
mor response and on patient early outcomes. 
Nevertheless, a number of reports indicate that the 
disease locally relapsed or progressed elsewhere, 
but only few reports indicated the value of electro-
chemotherapy in the local management of patient 
symptoms. Hence, the clinical benefit for patients, 
especially in the palliative setting, where preserva-
tion of quality of life (QoL) and evaluation of pa-
tient reported outcome (PRO) are crucial, should 
be based on dedicated assessments and described. 
The new RECIST (Response Evaluation Criteria 
in Solid Tumors) version 1.1 criteria, with some ad-
aptations, have proven a suitable tool for response 
assessment of superficial tumors21,72, whereas for 
the setting of treatment of deep-seated tumors (i.e., 
electrochemotherapy application on liver metas-
tases) the modified RECIST criteria represent the 
most appropriate and standardized method for 
the evaluation of tumor response.73 In general, for 
standard electrochemotherapy on superficial tu-
mors, the RECIST 1.1 criteria, which are based on 
one-dimensional measurements, seem even more 
practical and offer highly concordant response as-
sessment compared with the bidimensional WHO 
criteria.74 
So far, most of the published papers do not 
report on any serious treatment related adverse 
event after electrochemotherapy. Nevertheless, the 
process surrounding the determination, recording 
and reporting of adverse events remains moderate-
ly challenging especially for the clinician who may 
not be involved in drug or device-related research. 
Nevertheless, it is important to understand the ba-
sic definitions of adverse events reporting in order 
to ensure that the proper information is collected in 
clinical protocols. Moreover, a comprehensive pa-
tient observation and a detailed report of all types 
and grades of toxicities are essential for providing 
a comprehensive report of treatment outcome, not 
only in the early, but also in the long-term follow-
up. In this way, only large cohorts of patients will 
enable in-deep view of long-term toxicity and 
more detailed analyses of treatment-related ad-
verse events according to different patients sub-
group, as demonstrated by a recently published 
report on electrochemotherapy-related pain.43 For 
this purpose, Common Terminology Criteria for 
Adverse Events (CTCAE v4.0) is widely accepted 
throughout the oncology community as the stand-
ard classification and severity grading scale for 
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adverse events. Unfortunately, most of the studies 
conducted so far do not report consistently on this 
crucial aspect.
Key elements of treatment outcome 
assessment:
•  Time of response assessment 
•  Standardized response evaluation criteria 
(e.g. WHO, RECIST 1.1, mRECIST)
•  Time to local and systemic disease 
progression
•  Standardized toxicity criteria (e.g. CTCAE 
v4.0)
•  Quality of Life (QoL), patient reported 
outcomes (PRO)
•  Track of patients lost to follow-up
analysis and interpretation of the 
results 
A clear summary of the trial endpoints is essential. 
In fact, the field is moving beyond simply report-
ing on tumor control, as treatment now includes, 
in some instances, also primary tumors. Here it is 
important to report and discuss other parameters, 
such as time to local/systemic progression and, if 
possible, also the patient survival time and QoL as 
well. Such data will increase the evidence level of 
electrochemotherapy effectiveness, and consoli-
date a role for electrochemotherapy outside the 
palliative setting and into a confirmed primary 
treatment modality. 
It has been clearly demonstrated that tumor 
size is the most reliable predictive factor for re-
sponse in patients who underwent electrochemo-
therapy.21,22,69 In future, detailed reports including 
data on previous local therapies (e.g., radiation) as 
well as on local (within electrochemotherapy field) 
tissue status (e.g., presence of lymphedema or fi-
brosis) and concomitant/adjuvant oncologic treat-
ments would allow for the identification of other 
reliable predictive indicators for response.
Key elements for analysis and interpretation 
of the results: 
•  Summary of trial endpoints
•  Additional patient outcome parameters (e.g., 
QoL, PRO)
•  Predictive factors
•  Results interpretation
•  Future research directions
Conclusions
Electrochemotherapy represents an effective treat-
ment option for an increasing number of cancer 
patients with superficial tumors. Nevertheless, to 
further improve its evidence basis, it will be crucial 
to raise the quality of future reports. 
In this study, we have highlighted some relevant 
aspects of clinical data reporting, with the aim of 
improving the quality of future studies in the field 
of electrochemotherapy. Although a large amount 
of data are published so far, clinical research needs 
to adopt detailed and accurate reporting as well 
as moving from small, non-comparative series to 
well-designed, possibly randomized, clinical trials. 
Despite the encouraging results indicated, the vast 
majority of included reports are case series from 
single institutions. Although there was a wide con-
sensus to use previously published SOP for the 
treatment protocol, these studies often present a 
variety of designs and reporting methods, thus lim-
iting the understanding of patient selection, treat-
ment effect, toxicity and overall patient outcome. 
Of note, published studies often lack sufficient pro-
cedural as well as patient data. These shortcomings 
represent a major hurdle to performing systematic 
reviews or meta-analysis, which may provide a 
more robust evaluation of treatment effectiveness 
and, ultimately, encourage wider acceptance of 
electrochemotherapy in the clinical practice. 
Our study has some limitations. We identified a 
set of manuscript quality criteria from available lit-
erature and we have expanded this list by includ-
ing additional, procedure-specific criteria that were 
discussed and agreed among the authors. The list 
of 47 quality criteria that were used for reviewing 
published reports represents an arbitrary selection 
of criteria performed by a relatively small number 
of authors. There is potential for selection bias in 
the inclusion of papers for analysis, as the initial 
screen was based on broad, non-selective inclusion 
criteria. However, we feel that these were widely 
inclusive and fitting in order to develop the pro-
posed recommendations. Nevertheless, we believe 
that our suggestions largely cover the most crucial 
aspects, which are required to improve the quality 
of clinical practice and future research: trial design 
and conduction, definition of study endpoints, pa-
tient selection, treatment delivery, patient manage-
ment and follow-up, standardization of outcome 
assessment. Our recommendations are open to 
a broader discussion with the community users 
of electrochemotherapy and, possibly, to further 
improvements in line with other interventional 
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oncology procedures.75,76 Electrochemotherapy re-
quires standardization of terminology and report-
ing criteria to facilitate effective communication 
among researchers and appropriate comparison 
between different treatment technologies. As such, 
investigators involved in this field should be fa-
miliar with these recommendations and use them 
for future study design and conduction, treatment 
application as well as data reporting. We envision 
that the adoption of these recommendations will 
further improve the quality of future studies and 
allow more meaningful comparisons of outcome 
data of patients treated with electrochemotherapy 
(Supplementary file).
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